# Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

> **NCT03504852** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 331 (actual)

## Conditions studied

- Moderate to Severe Chronic Plaque-type Psoriasis

## Interventions

- **DRUG:** secukinumab 150 mg

## Key facts

- **NCT ID:** NCT03504852
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-25
- **Primary completion:** 2019-09-13
- **Final completion:** 2020-07-15
- **Target enrollment:** 331 (ACTUAL)
- **Last updated:** 2021-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03504852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03504852, "Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03504852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*